跳转至内容
Merck
CN

SML2283

Sigma-Aldrich

来那度胺

≥98% (HPLC)

登录查看公司和协议定价

别名:
来那度胺, 1-氧-4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚, 3-(4-氨基-1,3-二氢-1-氧代-2H-异吲哚-2-基)-2,6-哌啶二酮, 3-(4-氨基-1-氧代异吲哚-2-基)哌啶-2,6-二酮, CC 5013, CC-5013
经验公式(希尔记法):
C13H13N3O3
分子量:
259.26
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

ligand

lenalidomide

检测方案

≥98% (HPLC)

形式

powder

反应适用性

reagent type: ligand

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

O=C1N(C2CCC(NC2=O)=O)CC3=C1C=CC=C3N

InChI

1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

InChI key

GOTYRUGSSMKFNF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

来那度胺,沙利度胺的一种衍生物,是经批准可用于治疗多发性骨髓瘤的一种免疫调节剂。显然,来那度胺是泛素E3连接酶cereblon的一种配体,可诱导该酶降解Ikaros转录因子IKAROS家族锌指1(IKZF1)和IKZF3。来那度胺具有多效抗肿瘤作用。它可用于治疗5q缺失相关骨髓增生异常综合症(del(5q)-MDS)。

相关产品

产品编号
说明
价格

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Repr. 1B - STOT RE 2

靶器官

Blood

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Hila Shaim et al.
Frontiers in immunology, 8, 1773-1773 (2018-01-31)
Chronic lymphocytic leukemia (CLL) cells possess regulatory functions comparable to those of normal B10 cells, a regulatory B cell subset that suppresses effector T-cell function through STAT3-mediated IL-10 production. However, the mechanisms governing IL-10 production by CLL cells are not
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
Donovan KA, et al.
eLife, 7, e38430-e38430 (2018)
Antoine Domenger et al.
Frontiers in oncology, 13, 1110916-1110916 (2023-02-14)
Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are generally effective in newly diagnosed patients
Yuan Xiao Zhu et al.
Blood, 118(18), 4771-4779 (2011-08-24)
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of
Li Du et al.
Cancer gene therapy (2022-03-27)
Despite the potent effect of lenalidomide (Len) in multiple myeloma (MM) treatment, patients develop Len resistance leading to progressive disease, demanding an urgent need to investigate the mechanisms mediating Len resistance. Our study identified SUMOylation as a potential mechanism regulating

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门